An Extended Minimal Model of OGTT: Estimation of Alpha- and Beta-Cell Dysfunction, Insulin Resistance, and the Incretin Effect
Am J Physiol Endocrinol Metab. 2023 Dec 13. doi: 10.1152/ajpendo.00278.2023. Online ahead of print.ABSTRACTLoss of insulin sensitivity, alpha- and beta-cell dysfunction, and impairment in incretin effect have all been implicated in the pathophysiology of type 2 diabetes (T2D). Parsimonious mathematical models are useful in quantifying parameters related to the pathophysiology of T2D. Here we extend the minimum model developed to describe the glucose-insulin-glucagon dynamics in the intravenous glucose infusion (IIGI) experiment to the oral glucose tolerance test (OGTT). The extended model describes glucose and hormone dyna...
Source: American Journal of Physiology. Endocrinology and Metabolism - December 13, 2023 Category: Physiology Authors: Vijaya Subramanian Jonatan I Bagger Vinayak Harihar Jens J Holst Filip K Knop Tina Vilsb øll Source Type: research
An Extended Minimal Model of OGTT: Estimation of Alpha- and Beta-Cell Dysfunction, Insulin Resistance, and the Incretin Effect
Am J Physiol Endocrinol Metab. 2023 Dec 13. doi: 10.1152/ajpendo.00278.2023. Online ahead of print.ABSTRACTLoss of insulin sensitivity, alpha- and beta-cell dysfunction, and impairment in incretin effect have all been implicated in the pathophysiology of type 2 diabetes (T2D). Parsimonious mathematical models are useful in quantifying parameters related to the pathophysiology of T2D. Here we extend the minimum model developed to describe the glucose-insulin-glucagon dynamics in the intravenous glucose infusion (IIGI) experiment to the oral glucose tolerance test (OGTT). The extended model describes glucose and hormone dyna...
Source: Am J Physiol Endocri... - December 13, 2023 Category: Endocrinology Authors: Vijaya Subramanian Jonatan I Bagger Vinayak Harihar Jens J Holst Filip K Knop Tina Vilsb øll Source Type: research
An Extended Minimal Model of OGTT: Estimation of Alpha- and Beta-Cell Dysfunction, Insulin Resistance, and the Incretin Effect
Am J Physiol Endocrinol Metab. 2023 Dec 13. doi: 10.1152/ajpendo.00278.2023. Online ahead of print.ABSTRACTLoss of insulin sensitivity, alpha- and beta-cell dysfunction, and impairment in incretin effect have all been implicated in the pathophysiology of type 2 diabetes (T2D). Parsimonious mathematical models are useful in quantifying parameters related to the pathophysiology of T2D. Here we extend the minimum model developed to describe the glucose-insulin-glucagon dynamics in the intravenous glucose infusion (IIGI) experiment to the oral glucose tolerance test (OGTT). The extended model describes glucose and hormone dyna...
Source: American Journal of Physiology. Endocrinology and Metabolism - December 13, 2023 Category: Physiology Authors: Vijaya Subramanian Jonatan I Bagger Vinayak Harihar Jens J Holst Filip K Knop Tina Vilsb øll Source Type: research
An Extended Minimal Model of OGTT: Estimation of Alpha- and Beta-Cell Dysfunction, Insulin Resistance, and the Incretin Effect
Am J Physiol Endocrinol Metab. 2023 Dec 13. doi: 10.1152/ajpendo.00278.2023. Online ahead of print.ABSTRACTLoss of insulin sensitivity, alpha- and beta-cell dysfunction, and impairment in incretin effect have all been implicated in the pathophysiology of type 2 diabetes (T2D). Parsimonious mathematical models are useful in quantifying parameters related to the pathophysiology of T2D. Here we extend the minimum model developed to describe the glucose-insulin-glucagon dynamics in the intravenous glucose infusion (IIGI) experiment to the oral glucose tolerance test (OGTT). The extended model describes glucose and hormone dyna...
Source: Am J Physiol Endocri... - December 13, 2023 Category: Endocrinology Authors: Vijaya Subramanian Jonatan I Bagger Vinayak Harihar Jens J Holst Filip K Knop Tina Vilsb øll Source Type: research
An Extended Minimal Model of OGTT: Estimation of Alpha- and Beta-Cell Dysfunction, Insulin Resistance, and the Incretin Effect
Am J Physiol Endocrinol Metab. 2023 Dec 13. doi: 10.1152/ajpendo.00278.2023. Online ahead of print.ABSTRACTLoss of insulin sensitivity, alpha- and beta-cell dysfunction, and impairment in incretin effect have all been implicated in the pathophysiology of type 2 diabetes (T2D). Parsimonious mathematical models are useful in quantifying parameters related to the pathophysiology of T2D. Here we extend the minimum model developed to describe the glucose-insulin-glucagon dynamics in the intravenous glucose infusion (IIGI) experiment to the oral glucose tolerance test (OGTT). The extended model describes glucose and hormone dyna...
Source: American Journal of Physiology. Endocrinology and Metabolism - December 13, 2023 Category: Physiology Authors: Vijaya Subramanian Jonatan I Bagger Vinayak Harihar Jens J Holst Filip K Knop Tina Vilsb øll Source Type: research
An Extended Minimal Model of OGTT: Estimation of Alpha- and Beta-Cell Dysfunction, Insulin Resistance, and the Incretin Effect
Am J Physiol Endocrinol Metab. 2023 Dec 13. doi: 10.1152/ajpendo.00278.2023. Online ahead of print.ABSTRACTLoss of insulin sensitivity, alpha- and beta-cell dysfunction, and impairment in incretin effect have all been implicated in the pathophysiology of type 2 diabetes (T2D). Parsimonious mathematical models are useful in quantifying parameters related to the pathophysiology of T2D. Here we extend the minimum model developed to describe the glucose-insulin-glucagon dynamics in the intravenous glucose infusion (IIGI) experiment to the oral glucose tolerance test (OGTT). The extended model describes glucose and hormone dyna...
Source: Am J Physiol Endocri... - December 13, 2023 Category: Endocrinology Authors: Vijaya Subramanian Jonatan I Bagger Vinayak Harihar Jens J Holst Filip K Knop Tina Vilsb øll Source Type: research
An Extended Minimal Model of OGTT: Estimation of Alpha- and Beta-Cell Dysfunction, Insulin Resistance, and the Incretin Effect
Am J Physiol Endocrinol Metab. 2023 Dec 13. doi: 10.1152/ajpendo.00278.2023. Online ahead of print.ABSTRACTLoss of insulin sensitivity, alpha- and beta-cell dysfunction, and impairment in incretin effect have all been implicated in the pathophysiology of type 2 diabetes (T2D). Parsimonious mathematical models are useful in quantifying parameters related to the pathophysiology of T2D. Here we extend the minimum model developed to describe the glucose-insulin-glucagon dynamics in the intravenous glucose infusion (IIGI) experiment to the oral glucose tolerance test (OGTT). The extended model describes glucose and hormone dyna...
Source: American Journal of Physiology. Endocrinology and Metabolism - December 13, 2023 Category: Physiology Authors: Vijaya Subramanian Jonatan I Bagger Vinayak Harihar Jens J Holst Filip K Knop Tina Vilsb øll Source Type: research
An Extended Minimal Model of OGTT: Estimation of Alpha- and Beta-Cell Dysfunction, Insulin Resistance, and the Incretin Effect
Am J Physiol Endocrinol Metab. 2023 Dec 13. doi: 10.1152/ajpendo.00278.2023. Online ahead of print.ABSTRACTLoss of insulin sensitivity, alpha- and beta-cell dysfunction, and impairment in incretin effect have all been implicated in the pathophysiology of type 2 diabetes (T2D). Parsimonious mathematical models are useful in quantifying parameters related to the pathophysiology of T2D. Here we extend the minimum model developed to describe the glucose-insulin-glucagon dynamics in the intravenous glucose infusion (IIGI) experiment to the oral glucose tolerance test (OGTT). The extended model describes glucose and hormone dyna...
Source: Am J Physiol Endocri... - December 13, 2023 Category: Endocrinology Authors: Vijaya Subramanian Jonatan I Bagger Vinayak Harihar Jens J Holst Filip K Knop Tina Vilsb øll Source Type: research
An Intestinal FXR Agonist Mitigates Dysbiosis, Intestinal Tight Junctions, and Inflammation in High ‐Fat Diet‐Fed Mice
ConclusionFEX stimulates intestinal FXR and improves dysbiosis, intestinal TJs, and the release of incretins, mitigating glucose intolerance and BM increases induced by an HF diet. However, FEX results in glucose intolerance, insulin resistance, and reduces intestinal TJs in a control group, thus demonstrating limitations to this dietary model. (Source: Molecular Nutrition and Food Research)
Source: Molecular Nutrition and Food Research - December 12, 2023 Category: Food Science Authors: Tamiris Ingrid Petito ‐da‐Silva,
Felipe Missiba Villardi Júnior,
Aline Penna‐de‐Carvalho,
Carlos Alberto Mandarim‐de‐Lacerda,
Vanessa Souza‐Mello,
Sandra Barbosa‐da‐Silva Tags: Research Article Source Type: research
Advances in incretin-based therapeutics for obesity
Nature Reviews Endocrinology, Published online: 07 December 2023; doi:10.1038/s41574-023-00938-wThe year 2023 brought reports of highly effective glucagon-like peptide 1 (GLP1) mono-agonists or combinations with amylin receptor agonists. Results for monomolecular co-agonists that added glucagon receptor and/or glucose-dependent insulinotropic polypeptide (GIP) receptor agonism to GLP1 receptor activation were also published in 2023. Interestingly, antagonistic GIP receptor antibodies conjugated with a GLP1 agonist were also shown to be effective. (Source: Nature Reviews Endocrinology)
Source: Nature Reviews Endocrinology - December 7, 2023 Category: Endocrinology Authors: Mette M. Rosenkilde Source Type: research
Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships
Eur J Med Chem. 2023 Nov 25;264:115990. doi: 10.1016/j.ejmech.2023.115990. Online ahead of print.ABSTRACTFree fatty acid receptor 1 (FFAR1 or GPR40) is a potential target for treating type 2 diabetes mellitus (T2DM) and related disorders that have been extensively researched for many years. GPR40/FFAR1 is a promising anti-diabetic target because it can activate insulin, promoting glucose metabolism. It controls T2DM by regulating glucose levels in the body through two separate mechanisms: glucose-stimulated insulin secretion and incretin production. In the last few years, various synthetic GPR40/FFAR1 agonists have been di...
Source: European Journal of Medicinal Chemistry - December 1, 2023 Category: Chemistry Authors: Abhik Paul Sourin Nahar Pankaj Nahata Arnab Sarkar Avik Maji Ajeya Samanta Sanmoy Karmakar Tapan Kumar Maity Source Type: research
Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships
Eur J Med Chem. 2023 Nov 25;264:115990. doi: 10.1016/j.ejmech.2023.115990. Online ahead of print.ABSTRACTFree fatty acid receptor 1 (FFAR1 or GPR40) is a potential target for treating type 2 diabetes mellitus (T2DM) and related disorders that have been extensively researched for many years. GPR40/FFAR1 is a promising anti-diabetic target because it can activate insulin, promoting glucose metabolism. It controls T2DM by regulating glucose levels in the body through two separate mechanisms: glucose-stimulated insulin secretion and incretin production. In the last few years, various synthetic GPR40/FFAR1 agonists have been di...
Source: European Journal of Medicinal Chemistry - December 1, 2023 Category: Chemistry Authors: Abhik Paul Sourin Nahar Pankaj Nahata Arnab Sarkar Avik Maji Ajeya Samanta Sanmoy Karmakar Tapan Kumar Maity Source Type: research
Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships
Eur J Med Chem. 2023 Nov 25;264:115990. doi: 10.1016/j.ejmech.2023.115990. Online ahead of print.ABSTRACTFree fatty acid receptor 1 (FFAR1 or GPR40) is a potential target for treating type 2 diabetes mellitus (T2DM) and related disorders that have been extensively researched for many years. GPR40/FFAR1 is a promising anti-diabetic target because it can activate insulin, promoting glucose metabolism. It controls T2DM by regulating glucose levels in the body through two separate mechanisms: glucose-stimulated insulin secretion and incretin production. In the last few years, various synthetic GPR40/FFAR1 agonists have been di...
Source: European Journal of Medicinal Chemistry - December 1, 2023 Category: Chemistry Authors: Abhik Paul Sourin Nahar Pankaj Nahata Arnab Sarkar Avik Maji Ajeya Samanta Sanmoy Karmakar Tapan Kumar Maity Source Type: research
Anti-Incretin Gut Features Induced by Feed Supplementation with Alpha-Amylase: Studies on EPI Pigs
Int J Mol Sci. 2023 Nov 10;24(22):16177. doi: 10.3390/ijms242216177.ABSTRACTThe acini-islet-acinar (AIA) axis concept justifies the anatomical placement of the Langerhans islets within the exocrine pancreatic parenchyma and explains the existence of the pancreas as a single organ. Amylase has been suggested to play a key role as an anti-incretin factor. Oral glucose tolerance tests (OGTT) were performed on 18 piglets in both a healthy (prior to pancreatic duct ligation (PDL) surgery, study Day 10) and an exocrine pancreatic insufficient (EPI) state (30 days after PDL, study Day 48)). Amylase (4000 units/feeding) or Creon®...
Source: Molecular Medicine - November 25, 2023 Category: Molecular Biology Authors: Kateryna Pierzynowska Piotr Wychowa ński Kamil Zaworski Jaros ław Woliński Janine Donaldson Stefan Pierzynowski Source Type: research
Anti-Incretin Gut Features Induced by Feed Supplementation with Alpha-Amylase: Studies on EPI Pigs
Int J Mol Sci. 2023 Nov 10;24(22):16177. doi: 10.3390/ijms242216177.ABSTRACTThe acini-islet-acinar (AIA) axis concept justifies the anatomical placement of the Langerhans islets within the exocrine pancreatic parenchyma and explains the existence of the pancreas as a single organ. Amylase has been suggested to play a key role as an anti-incretin factor. Oral glucose tolerance tests (OGTT) were performed on 18 piglets in both a healthy (prior to pancreatic duct ligation (PDL) surgery, study Day 10) and an exocrine pancreatic insufficient (EPI) state (30 days after PDL, study Day 48)). Amylase (4000 units/feeding) or Creon®...
Source: Molecular Medicine - November 25, 2023 Category: Molecular Biology Authors: Kateryna Pierzynowska Piotr Wychowa ński Kamil Zaworski Jaros ław Woliński Janine Donaldson Stefan Pierzynowski Source Type: research
